Pfizer has expanded its manufacturing capabilities in Singapore with an SGD 1 billion (USD 0.77 billion) extension at its Tuas facility, focusing on the production of active pharmaceutical ingredients (APIs) for oncology, pain, and antibiotic medications. The highly automated facility is set to produce 11 types of API, seven of which are already being made at its first site, including a key ingredient for its best-selling breast cancer drug, Ibrance. This new facility, covering 429,000 square feet, will enhance Pfizer’s global supply chain by ensuring the continuity of API production across multiple sites.
The choice of Singapore for this significant investment reflects the country’s strategic importance as a leading biomedical sciences hub. Singapore’s strong talent pool, advanced manufacturing capabilities, and robust infrastructure make it an ideal location for pharmaceutical giants like Pfizer to expand their operations. The new facility will supply markets worldwide, including China, Brazil, Japan, Turkey, Europe, and the US, aligning with Singapore’s Manufacturing 2030 vision emphasizing innovation and resilience in drug production.
This expansion will create over 250 skilled jobs by 2026, further solidifying Singapore’s role in the global pharmaceutical industry. The Tuas II facility contributes to Pfizer’s global manufacturing network and strengthens Singapore’s preparedness and resilience in facing future health challenges.
(Source: The Business Times)
